Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
== Budget == The OECD operates on a two-year budget determined by member countries, with annual revenues over €900 million during the most recent reporting period (2023–2024). Totalling an estimated €229.9 million in 2024, assessed contributions to the "Part I Budget" are the largest single source of revenue for the OECD and these contributions are based on both the number of OECD members and the proportional size of their national economies.
==== Dietary recommendations ==== In the UK, the recommended daily values by the Dietary Reference Intake for magnesium are 300 mg for men and 270 mg for women. In the U.S. the Recommended Dietary Allowances (RDAs) are 400 mg for men ages 19–30 and 420 mg for older; for women 310 mg for ages 19–30 and 320 mg for older.
== Business model == In the period between 2006 and 2014, the company transitioned from print-centric to digital media, increasing digital revenues from 11% to 50% of total revenues. The company's growth during this period came from both "organic" growth and strategic acquisitions. In 2009 the firm was described as a "business to business magazine publisher", which could be interpreted as a publisher of trade magazines. In 2018, the organization transitioned fully from a digital media organization to a digital marketing organization, following market trends. As such, the company changed its name from Advantage Business Media to Advantage Business Marketing, updated its logo, and began the overhaul of its digital websites and assets. The organization offered digital marketing services including inbound marketing, branding, automation services, customer relationship management integration, and data management.
Sources: en.wikipedia.org
In Colombia, the laundering of billions of dollars, which come from drug trafficking, is carried out through imports of contraband from the parallel exchange market. In Central American countries such as Guatemala and Honduras, money laundering continues to increase in the absence of adequate legislation and regulations in these countries. Money laundering activities in Costa Rica have experienced substantial growth, especially using large-scale currency smuggling and investments of drug cartels in real estate, within the tourism sector. Furthermore, the Colon Free Zone in Panama, continues to be the area of operations for money laundering where cash is exchanged for products of different nature that are then put up for sale at prices below those of production for a return fast of the capital. In Mexico, the preferred techniques continue to be the smuggling of currency abroad, in addition to electronic transfers, bank drafts with Mexican banks and operations in the parallel exchange market. Money Laundering in the Caribbean countries continues to be a serious problem that seems to be very dangerous. Specifically, in Antigua, the Dominican Republic, Jamaica, Saint Vincent and the Grenadines. Citizens of the Dominican Republic who have been involved in money laundering in the United States, use companies that are dedicated to transferring funds sent to the Dominican Republic in amounts of less than $10,000 under the use of false names. Moreover, in Jamaica, multimillion-dollar asset laundering cases were discovered through telephone betting operations abroad.
== Particular oligomeric prodelphinidins == Prodelphinidin B3 (gallocatechin-(4α→8)-catechin) and prodelphinidin B9 (epigallocatechin-(4α→8)-catechin) can be isolated in beer. Prodelphinidin C2 (gallocatechin-(4α→8)-gallocatechin-(4α→8)-catechin) can be isolated in malt. The A-type proanthocyanidin epigallocatechin-(2β→7,4β→8)-epicatechin can be found in the leaves of Dioclea lasiophylla,
=== Prenatal tests === A prenatal test can be considered when the mother is a known or suspected carrier. Before invasive testing, determination of the fetal sex is important; while males are sometimes affected by this X-linked disease, female Duchenne muscular dystrophy is extremely rare. This can be achieved by ultrasound scan at 16 weeks or more recently by free fetal DNA (cffDNA) testing. Chorion villus sampling (CVS) can be done at 11–14 weeks and has a 1% risk of miscarriage. Amniocentesis can be done after 15 weeks and has a 0.5% risk of miscarriage. Non invasive prenatal testing can be done around 10–12 weeks. Another option in the case of unclear genetic test results is fetal muscle biopsy.
1993/1063) A43 Trunk Road (Silverstone Bypass) (Detrunking) Order 1993 (S.I. 1993/1064) North Norfolk Action (Miscellaneous Provisions) Order 1993 (S.I. 1993/1065) Gipsy Encampments (Metropolitan District of Sefton) Order 1993 (S.I. 1993/1066) Airports Slot Allocation Regulations 1993 (S.I. 1993/1067) Oldham National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1068) Cornwall and Isles of Scilly Mental Handicap National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1069) Merchant Shipping (Vessels in Commercial Use for Sport or Pleasure) Regulations 1993 (S.I. 1993/1072) Aviation Security (Air Cargo Agents) Regulations 1993 (S.I. 1993/1073) Vocational Training (Public Financial Assistance and Disentitlement to Tax Relief) (Amendment) Regulations 1993 (S.I. 1993/1074) Plymouth Development Corporation (Planning Functions) Order 1993 (S.I. 1993/1075) Social Security (Consequential Provisions) (Northern Ireland) Act 1992 Appointed Day Order 1993 (S.I. 1993/1079) Vocational Training (Tax Relief) (Amendment) Regulations 1993 (S.I. 1993/1082) Peak Rail Light Railway Order 1993 (S.I. 1993/1083) Dacorum and St Albans Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1084) Rochdale Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1085) Horizon National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1086) Bexley and Greenwich (London Borough Boundaries) Order 1993 (S.I. 1993/1091) Insurance Companies (Cancellation No.
Sources: en.wikipedia.org
Hofmann rearrangement of 3,4,5-trimethoxyphenylpropionamide. Cyanohydrin reaction between potassium cyanide and 3,4,5-trimethoxybenzaldehyde followed by acetylation and reduction. Henry reaction of 3,4,5-trimethoxybenzaldehyde with nitromethane followed by nitro compound reduction of ω-nitrotrimethoxystyrene. This was the method used by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). Ozonolysis of elemicin followed by reductive amination. Ester reduction of Eudesmic acid's methyl ester followed by halogenation, Kolbe nitrile synthesis, and nitrile reduction. Amide reduction of 3,4,5-trimethoxyphenylacetamide. Reduction of 3,4,5-trimethoxy(2-nitrovinyl)benzene with lithium aluminum hydride. Treatment of tricarbonyl-(η6-1,2,3-trimethoxybenzene) chromium complex with acetonitrile carbanion in THF and iodine, followed by reduction of the nitrile with lithium aluminum hydride.
==== Cancer ==== The first study on trained dogs used for the detection of cancer was published by Willis et al. in 2004, observing that dogs were capable of detecting bladder cancer from urine samples. Subsequently, in 2004, Pickel et al. confirmed that dogs were able to successfully diagnose melanoma. In 2008, Horvath et al. confirmed dogs were successful in differentiating between cancerous and normal tissue and in distinguishing non-cancerous pathological tissue from cancerous tissue. Another study by Horvath et al. in 2010 found the dogs to show over 90% specificity in detecting ovarian cancer from blood samples, colorectal cancer from respiratory air, and prostate cancer from dog urine.
== Interactions == Being metabolized only to a small extent, the substance has a low potential for interactions. In studies, inhibitors of the liver enzymes CYP3A4, CYP2C19, and CYP2C9, as well as the CYP3A4 inducer rifampicin, had no relevant influence on baricitinib concentrations in the bloodstream. While baricitinib blocks a number of transporter proteins in vitro, clinically relevant interactions via this mechanism are considered very unlikely, except perhaps for the cation transporter SLC22A1 (OCT1). An additive effect with other immunosuppressants cannot be excluded.
Mōri Motonari issued each soldier a bag of rice, fried rice, and mochi, the latter of which was chosen due to its portability, long shelf life, ability to provide high energy in small amounts, and Motonari's personal preference for it. Uesugi Kenshin would prepare massive feasts for his army before battles, known as kachidoki-meshi ("victory cry meals"), featuring delicacies such as "a mountain of rice ... black-boiled abalone, vinegar-washed fish and jellyfish sashimi, soups with seasonal vegetables and dried fish, walnut-roasted duck, simmered sand borer, and more", though Kenshin himself was noted to eat very little. During battles, Kenshin assembled supply convoys called konidatai staffed by peasants, who would deliver supplies and rations to troops. Toyotomi Hideyoshi is said to have regularly distributed food rations out to his officers and soldiers, and kept them well-fed. In one instance, while traveling from Ogaki to Nagahama (a 52 kilometer distance) in 1583, Hideyoshi sent scouts ahead to each village to ask that they prepare rice for Hideyoshi's army; the villages set out rice balls for the soldiers, allowing them to remain fed for the entire trip. In general, Japanese soldiers would bring uchigaibukuro, pouches used to store rice and medicine, into battle with them. They would also eat miso, dried taro stalk, and okayu as part of a soup prepared in a soldier's jingasa.
== History == Frederick L. "Freddy" Simon grew up in Colwich, Kansas, near Wichita. He was a World War II veteran, joining the U.S. Army infantry in 1943 and serving in the 1st Cavalry Division. He was awarded the Purple Heart due to combat wounds sustained in the Pacific Theater, as well as a Bronze Star for valor. After the war, Simon worked for the same company in the hospitality industry for 55 years, building connections with many restaurateurs. Freddy lent his name to, and was a business partner in, a Simon family-owned restaurant called Freddy's Frozen Custard & Steakburgers. Founded by his sons Randy and Bill and Bill's friend, restaurateur Scott Redler, the first location opened in Wichita on August 26, 2002. Freddy's quickly gained a loyal customer base, leading to further expansion beginning in 2004. Freddy's menu has remained consistent over the years, offering signature steakburgers, Vienna Beef hot dogs, and fresh frozen custard desserts across all locations. The food was based on "All American" meals that Freddy had served his own family, with the setting of the restaurant based on fast-casual dining of the late 1940s and early 1950s, evoking "a post-war era of optimism, pride, and values focusing on unity and quality family time." On December 17, 2016, Freddy's co-founder Bill Simon died at the age of 61 after a battle with cancer. Freddy Simon died at the age of 95 on October 25, 2020. In March 2021, private equity firm Thompson Street Capital Partner purchased Freddy's Frozen Custard & Steakburgers for an undisclosed amount.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.